|
1
|
Coughlin SS, Matthews-Juarez P, Juarez PD,
Melton CE and King M: Opportunities to address lung cancer
disparities among African Americans. Cancer Med. 3:1467–1476. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Detterbeck FC, Mazzone PJ, Naidich DP and
Bach PB: Screening for lung cancer: Diagnosis and management of
lung cancer, 3rd ed: American College of Chest Physicians
evidence-based clinical practice guidelines. Chest. 143(Suppl 5):
e78S–e92S. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nana-Sinkam SP and Powell CA: Molecular
biology of lung cancer: Diagnosis and management of lung cancer,
3rd ed: American College of Chest Physicians evidence-based
clinical practice guidelines. Chest. 143(Suppl 5): e30S–e39S. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
López-Lázaro M, Pastor N, Azrak SS, Ayuso
MJ, Austin CA and Cortés F: Digitoxin inhibits the growth of cancer
cell lines at concentrations commonly found in cardiac patients. J
Nat Prod. 68:1642–1645. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kometiani P, Liu L and Askari A:
Digitalis-induced signaling by Na+/K+-ATPase
in human breast cancer cells. Mol Pharmacol. 67:929–936. 2005.
View Article : Google Scholar
|
|
6
|
Einbond LS, Wu HA, Su T, Chang T,
Panjikaran M, Wang X and Goldsberry S: Digitoxin activates EGR1 and
synergizes with paclitaxel on human breast cancer cells. J
Carcinog. 9:102010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Elbaz HA, Stueckle TA, Tse W, Rojanasakul
Y and Dinu CZ: Digitoxin and its analogs as novel cancer
therapeutics. Exp Hematol Oncol. 1:42012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Socinski MA: Update on taxanes in the
first-line treatment of advanced non-small-cell lung cancer. Curr
Oncol. 21:e691–e703. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lück HJ and Roché H: Weekly paclitaxel: An
effective and well-tolerated treatment in patients with advanced
breast cancer. Crit Rev Oncol Hematol. 44(Suppl): S15–S30. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Das V, Štěpánková J, Hajdúch M and Miller
JH: Role of tumor hypoxia in acquisition of resistance to
microtubule-stabilizing drugs. Biochim Biophys Acta. 1855:172–182.
2015.PubMed/NCBI
|
|
11
|
Zasadil LM, Andersen KA, Yeum D, Rocque
GB, Wilke LG, Tevaarwerk AJ, Raines RT and Burkard ME: Cytotoxicity
of paclitaxel in breast cancer is due to chromosome missegregation
on multipolar spindles. Sci Transl Med. 6:229ra432014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wiernik PH, Schwartz EL, Strauman JJ,
Dutcher JP, Lipton RB and Paietta E: Phase I clinical and
pharmacokinetic study of taxol. Cancer Res. 47:2486–2493.
1987.PubMed/NCBI
|
|
13
|
Veale D, Cantwell BM, Kerr N, Upfold A and
Harris AL: Phase 1 study of high-dose hydroxyurea in lung cancer.
Cancer Chemother Pharmacol. 21:53–56. 1988.PubMed/NCBI
|
|
14
|
Kang SR, Song HC, Byun BH, Oh JR, Kim HS,
Hong SP, Kwon SY, Chong A, Kim J, Cho SG, et al: Intratumoral
metabolic heterogeneity for prediction of disease progression after
concurrent chemoradiotherapy in patients with inoperable stage III
non-small-cell lung cancer. Nucl Med Mol Imaging. 48:16–25. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Neelakantan D, Drasin DJ and Ford HL:
Intratumoral heterogeneity: Clonal cooperation in
epithelial-to-mesenchymal transition and metastasis. Cell Adh Migr.
9:1–12. 2015. View Article : Google Scholar
|
|
16
|
Cheng X and Chen H: Tumor heterogeneity
and resistance to EGFR-targeted therapy in advanced nonsmall cell
lung cancer: Challenges and perspectives. Onco Targets Ther.
7:1689–1704. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Iyer AK, Zhou M, Azad N, Elbaz H, Wang L,
Rogalsky DK, Rojanasakul Y, O'Doherty GA and Langenhan JM: A direct
comparison of the anticancer activities of digitoxin
MeON-Neoglycosides and O-Glycosides: Oligosaccharide chain
length-dependent induction of caspase-9-mediated apoptosis. ACS Med
Chem Lett. 1:326–330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Medan D, Luanpitpong S, Azad N, Wang L,
Jiang BH, Davis ME, Barnett JB, Guo L and Rojanasakul Y:
Multifunctional role of Bcl-2 in malignant transformation and
tumorigenesis of Cr(VI)-transformed lung cells. PLoS One.
7:e370452012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rafehi H, Orlowski C, Georgiadis GT,
Ververis K, El-Osta A and Karagiannis TC: Clonogenic assay:
Adherent cells. J Vis Exp. 49:25732011.PubMed/NCBI
|
|
20
|
Park S, Kim JH, Hwang YI, Jung KS, Jang YS
and Jang SH: Schedule-dependent effect of
epigallocatechin-3-gallate (EGCG) with paclitaxel on H460 cells.
Tuberc Respir Dis (Seoul). 76:114–119. 2014. View Article : Google Scholar
|
|
21
|
Kues WA, Anger M, Carnwath JW, Paul D,
Motlik J and Niemann H: Cell cycle synchronization of porcine fetal
fibroblasts:Effects of serum deprivation and reversible cell cycle
inhibitors. Biol Reprod. 62:412–419. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Khammanit R, Chantakru S, Kitiyanant Y and
Saikhun J: Effect of serum starvation and chemical inhibitors on
cell cycle synchronization of canine dermal fibroblasts.
Theriogenology. 70:27–34. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Maurer-Schultze B, Siebert M and Bassukas
ID: An in vivo study on the synchronizing effect of hydroxyurea.
Exp Cell Res. 174:230–243. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Darzynkiewicz Z, Halicka HD, Zhao H and
Podhorecka M: Cell synchronization by inhibitors of DNA replication
induces replication stress and DNA damage response: Analysis by
flow cytometry. Methods Mol Biol. 761:85–96. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Brower M, Carney DN, Oie HK, Gazdar AF and
Minna JD: Growth of cell lines and clinical specimens of human
non-small cell lung cancer in a serum-free defined medium. Cancer
Res. 46:798–806. 1986.PubMed/NCBI
|
|
26
|
Soriano AF, Helfrich B, Chan DC, Heasley
LE, Bunn PAJ Jr and Chou TC: Synergistic effects of new
chemopreventive agents and conventional cytotoxic agents against
human lung cancer cell lines. Cancer Res. 59:6178–6184. 1999.
|
|
27
|
Kroep JR, Giaccone G, Tolis C, Voorn DA,
Loves WJ, Groeningen CJ, Pinedo HM and Peters GJ: Sequence
dependent effect of paclitaxel on gemcitabine metabolism in
relation to cell cycle and cytotoxicity in non-small-cell lung
cancer cell lines. Br J Cancer. 83:1069–1076. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zoli W, Ricotti L, Barzanti F, Dal Susino
M, Frassineti GL, Milandri C, Casadei Giunchi D and Amadori D:
Scheduledependent interaction of doxorubicin, paclitaxel and
gemcitabine in human breast cancer cell lines. Int J Cancer.
80:413–416. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Oliveras-Ferraros C, Vazquez-Martin A,
Colomer R, De Llorens R, Brunet J and Menendez JA:
Sequence-dependent synergism and antagonism between paclitaxel and
gemcitabine in breast cancer cells: The importance of scheduling.
Int J Oncol. 32:113–120. 2008.
|
|
30
|
Cheng H, An SJ, Zhang XC, Dong S, Zhang
YF, Chen ZH, Chen HJ, Guo AL, Lin QX and Wu YL: In vitro
sequencedependent synergism between paclitaxel and gefitinib in
human lung cancer cell lines. Cancer Chemother Pharmacol.
67:637–646. 2011. View Article : Google Scholar
|
|
31
|
Baldan F, Mio C, Allegri L, Puppin C,
Russo D, Filetti S and Damante G: Synergy between HDAC and PARP
inhibitors on proliferation of a human anaplastic thyroid
cancer-derived cell line. Int J Endocrinol. 2015:9783712015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gerlinger M, Rowan AJ, Horswell S, Larkin
J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A,
Tarpey P, et al: Intratumor heterogeneity and branched evolution
revealed by multiregion sequencing. N Engl J Med. 366:883–892.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang DM, Guh JH, Huang YT, Chueh SC, Wang
HP and Teng CM: Cardiac glycosides induce resistance to
tubulindependent anticancer drugs in androgen-independent human
prostate cancer. J Biomed Sci. 9:443–452. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Larzabal L, El-Nikhely N, Redrado M,
Seeger W, Savai R and Calvo A: Differential effects of drugs
targeting cancer stem cell (CSC) and non-CSC populations on lung
primary tumors and metastasis. PLoS One. 8:e797982013. View Article : Google Scholar : PubMed/NCBI
|
